<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In a retrospective study of 352 patients with primary <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, 61 (17.3%) revealed <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> in bone marrow biopsies </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:mp ids='MP_0003045'>fibrosis</z:mp> was observed to occur mostly focally (41/61 cases), and collagen deposits were found very rarely (4/61) </plain></SENT>
<SENT sid="2" pm="."><plain>The histopathology of bone marrow biopsies revealed <z:mpath ids='MPATH_134'>hyperplasia</z:mpath> and disturbed differentiation in megakaryopoiesis; the frequency and grade of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> in megakaryopoiesis increased with advancing <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Reticulin <z:mp ids='MP_0003045'>fibrosis</z:mp> occurred in <z:hpo ids='HP_0000001'>all</z:hpo> subtypes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; however, there was a higher incidence in <z:hpo ids='HP_0011010'>chronic</z:hpo> myelo-<z:mpath ids='MPATH_502'>monocytic leukaemia</z:mpath> (CMMoL) </plain></SENT>
<SENT sid="4" pm="."><plain>The frequency of cytogenetic aberrations was significantly higher in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases with <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo>, compared to the cases without <z:mp ids='MP_0003045'>fibrosis</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Clinical data showed significantly lower values of <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> and lower platelet counts in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Life expectancy was reduced to 9.6 months, compared with 17.4 months in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> without <z:mp ids='MP_0003045'>fibrosis</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>In refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo>, the survival times were 10.0 months in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo>, compared to 28.9 months in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> without <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>36.6% of the patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> developed a transformation into ANLL during the course of the disease </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0011974'>Myelofibrosis</z:hpo> therefore seems to herald a poor prognosis </plain></SENT>
</text></document>